Drugs / MHB048C
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07192120 | Jan 2026 → Oct 2029 expected | castration-resistant prostate carcinoma | Minghui Pharmaceutical (Hangzhou) Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MHB048C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07192120 ↗ |
| Route | Intravenous | “IV administration of MHB048C Q2W or Q3W” NCT07192120 ↗ |